Amlitelimab, a fully human non-T cell depleting monoclonal antibody that selectively targets OX40-ligand (OX40L), is safe and ...

At the 2026 American Academy of Dermatology Annual Meeting in Denver, Kenvue’s Neutrogena, Aveeno and Rogaine brands ...

Access resources to help you promote the specialty in your community and beyond.

One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety ...

Presentations at the 2026 meeting of the American Academy of Dermatology not only demonstrate the therapeutic potential of ...

At the American Academy of Dermatology (AAD) 2026 Annual Meeting, experts emphasized the value of in-person networking, ...

For adults with dermatomyositis, brepocitinib, an oral tyrosine kinase 2/Janus kinase 1 inhibitor, demonstrates significant ...

Ixekizumab plus tirzepatide (IXE+TZP) shows significant benefits for outcomes in psoriatic arthritis (PsA) versus IXE alone ...

AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research sessionAcross the COAST 1, ...

Galderma (SIX: GALD), the pure-play dermatology category leader, will present the latest updates on its innovations across its broad portfolio at the 2026 American Academy of Dermatology (AAD) Annual ...

HealthDay News — Treatment with upadacitinib is safe and effective for adults and adolescents with nonsegmental vitiligo (NSV), according to a study presented at the annual meeting of the American ...

There's very little parents can do to prevent their kids from developing eczema, according to new guidelines from the ...